Outlook Therapeutics OTLK
NASDAQ OTLK
$0.48 +0.02 (+4.43%)
At close: Nov 11, 2026 · 4:00 PM EST

Outlook Therapeutics (OTLK) Net Income Attributable to Noncontrolling Interests (2015)

Updated

Outlook Therapeutics' Net Income Attributable to Noncontrolling Interests was -$896,136 in fiscal Q4 2015 (quarter ended Sep 30, 2015).

Analysis

Outlook Therapeutics (OTLK) Net Income Attributable to Noncontrolling Interests (2015) Analysis & Trends

For FY2015 (ended Sep 30, 2015), Net Income Attributable to Noncontrolling Interests at Outlook Therapeutics came in at -$1.28 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) NCI Net Income (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 2.00 Mn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 2.00 Mn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -1.00 Mn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 10.00 Mn
10 Outlook Therapeutics 62.90 Mn 27.15 Mn -8,265.00 -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2015 -896,136.00
Jun 30, 2015 -380,435.00
API Access

Outlook Therapeutics Net Income Attributable to Noncontrolling Interests API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=OTLK&period=max&api_key=YOUR_API_KEY